메뉴 건너뛰기




Volumn 68, Issue 4, 2013, Pages 972-974

Pharmacokinetic interaction of maraviroc with tacrolimus in a patient coinfected with HIV and hepatitis B virus following hepatic transplant due to hepatocellular carcinoma

Author keywords

HBV; Hepatic transplantation; HIV antiviral pharmacology; Immunosuppression

Indexed keywords

ALPHA FETOPROTEIN; EFAVIRENZ; EMTRICITABINE; HEPATITIS B SURFACE ANTIBODY; MARAVIROC; PREDNISOLONE; TACROLIMUS; TENOFOVIR;

EID: 84875242373     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks486     Document Type: Letter
Times cited : (7)

References (5)
  • 1
    • 34848869334 scopus 로고    scopus 로고
    • CCR5 blockade modulates inflammation and alloimmunity in primates
    • Schröder C, Pierson RN, Nguyen B. CCR5 blockade modulates inflammation and alloimmunity in primates. J Immunol 2007; 179: 2289-99.
    • (2007) J Immunol , vol.179 , pp. 2289-2299
    • Schröder, C.1    Pierson, R.N.2    Nguyen, B.3
  • 2
    • 79953210368 scopus 로고    scopus 로고
    • CCR5 blockade in combination with cyclosporine increased cardiac graft survival and generated alternatively activated macrophages in primates
    • Li J, Chen G, Ye P et al. CCR5 blockade in combination with cyclosporine increased cardiac graft survival and generated alternatively activated macrophages in primates. J Immunol 2011; 186: 3753-61.
    • (2011) J Immunol , vol.186 , pp. 3753-3761
    • Li, J.1    Chen, G.2    Ye, P.3
  • 3
    • 51649088021 scopus 로고    scopus 로고
    • Maraviroc: in vitro assessment of drug-drug interaction potential
    • Hyland R, Dickins M, Collins C et al. Maraviroc: in vitro assessment of drug-drug interaction potential. Br J Clin Pharm 2008; 66: 498-507.
    • (2008) Br J Clin Pharm , vol.66 , pp. 498-507
    • Hyland, R.1    Dickins, M.2    Collins, C.3
  • 5
    • 40549135975 scopus 로고    scopus 로고
    • Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist
    • Abel S, van der Ryst E, Rosario MC et al. Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers. Br J Clin Pharm 2008; 65 Suppl 1: 5-18.
    • (2008) in healthy volunteers. Br J Clin Pharm , vol.65 , Issue.SUPPL.1 , pp. 5-18
    • Abel, S.1    van der Ryst, E.2    Rosario, M.C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.